Literature DB >> 3015014

Characterization of a varicella-zoster virus variant with altered thymidine kinase activity.

S Shigeta, S Mori, T Yokota, K Konno, E De Clercq.   

Abstract

A varicella-zoster virus (VZV) strain resistant to 5-iodo-2'-deoxyuridine (IdUrd) and 5-bromo-2'-deoxyuridine (BrdUrd) but sensitive to (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVdUrd) and (E)-5-(2-iodovinyl)-2'-deoxyuridine (IVdUrd) was isolated. The 2'-deoxythymidine (dThd) kinase of this mutant (Ito) strain was characterized; it was much less efficient in phosphorylating dThd, 2'-deoxycytidine, and BrdUrd than were the dThd kinases from wild-type (CaQu, Kobayashi) VZV strains. The Ito dThd kinase had a markedly decreased affinity for dThd, 2'-deoxycytidine, and BrdUrd but only a slightly decreased affinity for IVdUrd than had the wild-type VZV dThd kinase. BrdUrd was incorporated to a much lesser extent in VZV (Ito strain)-infected cells than wild-type VZV-infected cells, but IVdUrd was incorporated in Ito VZV-infected cells as efficiently as in wild-type VZV-infected cells. While resistant to IdUrd and BrdUrd, the Ito strain was susceptible to inhibitors of de novo thymidylate biosynthesis such as aminopterin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3015014      PMCID: PMC180499          DOI: 10.1128/AAC.29.6.1053

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  MUTANT STRAINS OF HERPES SIMPLEX DEFICIENT IN THYMIDINE KINASE-INDUCING ACTIVITY.

Authors:  D R DUBBS; S KIT
Journal:  Virology       Date:  1964-04       Impact factor: 3.616

2.  The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice.

Authors:  H J Field; P Wildy
Journal:  J Hyg (Lond)       Date:  1978-10

3.  Deoxypyrimidine nucleoside metabolism in varicella-zoster virus-infected cells.

Authors:  T Hackstadt; L P Mallavia
Journal:  J Virol       Date:  1978-02       Impact factor: 5.103

4.  Live vaccine used to prevent the spread of varicella in children in hospital.

Authors:  M Takahashi; T Otsuka; Y Okuno; Y Asano; T Yazaki
Journal:  Lancet       Date:  1974-11-30       Impact factor: 79.321

5.  Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance.

Authors:  G Darby; H J Field; S A Salisbury
Journal:  Nature       Date:  1981-01-01       Impact factor: 49.962

6.  Properties of a novel thymidine kinase induced by an acyclovir-resistant herpes simplex virus type 1 mutant.

Authors:  B A Larder; G Darby
Journal:  J Virol       Date:  1982-05       Impact factor: 5.103

7.  In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds.

Authors:  E De Clercq; J Descamps; M Ogata; S Shigeta
Journal:  Antimicrob Agents Chemother       Date:  1982-01       Impact factor: 5.191

8.  Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

Authors:  L E Schnipper; C S Crumpacker
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

9.  Two distinct loci confer resistance to acycloguanosine in herpes simplex virus type 1.

Authors:  D M Coen; P A Schaffer
Journal:  Proc Natl Acad Sci U S A       Date:  1980-04       Impact factor: 11.205

10.  The sensitivity of acyclovir-resistant mutants of herpes simplex virus to other antiviral drugs.

Authors:  H Field; A McMillan; G Darby
Journal:  J Infect Dis       Date:  1981-02       Impact factor: 5.226

View more
  6 in total

Review 1.  Resistance of herpesviruses to antiviral drugs.

Authors:  P A Chatis; C S Crumpacker
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

2.  Generation of a reporter cell line for detection of infectious varicella-zoster virus and its application to antiviral studies.

Authors:  Guan-Qing Wang; Tatsuo Suzutani; Yumiko Yamamoto; Yoshiko Fukui; Naoki Nozawa; D Scott Schmid; Ichiro Kurane; Naoki Inoue
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  In vitro activity of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine against newly isolated clinical varicella-zoster virus strains.

Authors:  M Baba; K Konno; S Shigeta; E De Clercq
Journal:  Eur J Clin Microbiol       Date:  1987-04       Impact factor: 3.267

5.  Inhibition of varicella-zoster virus-induced DNA polymerase by a new guanosine analog, 9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine triphosphate.

Authors:  G Abele; B Eriksson; J Harmenberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

6.  Mutant varicella-zoster virus thymidine kinase: correlation of clinical resistance and enzyme impairment.

Authors:  G B Roberts; J A Fyfe; R K Gaillard; S A Short
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.